COVID-19: Vaccines and Therapeutics
The Centers for Disease Control and Prevention updated requirements for health care providers participating in the COVID-19 Vaccination Program to clarify that participants may not sell or divert COVID-19 vaccine or ancillary materials purchased for the program; reproduce the program’s COVID-19…
The Food and Drug Administration authorized for emergency use one more batch of drug substance manufactured for the Janssen (Johnson & Johnson) COVID-19 vaccine at an Emergent BioSolutions facility in Baltimore.
Rhode Island health care providers may no longer order the monoclonal antibodies bamlanivimab and etesevimab until further notice due to rising prevalence of the SARS-CoV-2 P.1 and B.1.351 variants, which are not susceptible to the combination therapy, the Department of Health and Human Services’…
Moderna Inc. announced an agreement with the U.S. government for the purchase of an additional 200 million doses of Moderna’s COVID-19 vaccine, along with an option to purchase other COVID-19 vaccine candidates in the biotech company’s development pipeline.
The Living Learning Network’s pandemic reflection book showcases the defining moments of COVID-19 as told by the front lines.
Only 11% of pregnant women in the Centers for Disease Control and Prevention’s Vaccine Safety Datalink, which includes vaccine safety monitoring data from nine integrated health systems, were fully vaccinated against COVID-19 by May 8, compared with 25% of non-pregnant women, the CDC reported.
The Health Resources and Services Administration awarded 14 organizations grants to hire people to support COVID-19 vaccination and outreach in vulnerable and medically underserved communities.
The Food and Drug Administration Friday authorized for emergency use two batches of drug substance manufactured for the Janssen (Johnson & Johnson) COVID-19 vaccine at an Emergent BioSolutions facility in Baltimore.
Novavax announced phase 3 trial results for its COVID-19 vaccine, saying it provides 100% protection against moderate and severe disease, with a 90.4% overall efficacy.
During this webinar, the authors of a report discuss the various archetypes of hesitant populations and strategies for communicating with them based on their particular mindset and attitude. A second panel discussion among a clinician, strategist and community health professional, will explore how…